Pharmacokinetics, efficacy, and safety of a plasma-derived VWF/FVIII concentrate (VONCENTO) for on-demand and prophylactic treatment in patients with von Willebrand disease (SWIFT-VWD study)

@inproceedings{Lissitchkov2017PharmacokineticsEA,
  title={Pharmacokinetics, efficacy, and safety of a plasma-derived VWF/FVIII concentrate (VONCENTO) for on-demand and prophylactic treatment in patients with von Willebrand disease (SWIFT-VWD study)},
  author={Toshko J. Lissitchkov and Evgeny Buevich and Kazimierz Kuliczkowski and Oleksandra Stasyshyn and M{\^o}nica Hermida Cerqueira and Anna Klukowska and Christine Joch and Wilfried Seifert},
  booktitle={Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis},
  year={2017}
}
VONCENTO (CSL Behring Gmbh, Marburg, Germany) is a plasma-derived, high concentration, lower volume [relative to HAEMATE P (CSL Behring)], high-purity von Willebrand factor (VWF)/factor VIII (FVIII) concentrate with a VWF/FVIII ratio similar to HAEMATE P. This open-label, multicentre study investigated the pharmacokinetic, haemostatic efficacy, and safety… CONTINUE READING